Companies › BRVE

BRVE 10-K & 10-Q changes, risk factors and insider trading

Braveheart Bio, Inc. · Nasdaq · Pharmaceutical Preparations · CIK 2131524 · All filings on SEC.gov

Everything below is quoted or computed from Braveheart Bio, Inc.'s public SEC filings. It is not a recommendation to buy or sell. Automated comparisons can contain errors; confirm with the original filing.

At a glance

10Form 4 filings reporting open-market purchases (last 180 days)
0Form 4 filings reporting open-market sales (last 180 days)

Jump to: Annual report (10-K) · Quarterly report (10-Q) · Insider transactions · 13F holders

What changed in the latest 10-K

Comparison not available: Not available: fewer than two 10-K filings on EDGAR to compare..

What changed in the latest 10-Q

Comparison not available: Not available: fewer than two 10-Q filings on EDGAR to compare (only one so far)..

BRVE insider buying and selling (Form 4)

Since 2026-04-11, insiders reported open-market purchases in 10 Form 4 filings (10 insiders, 1 trade date, 8,835,275 shares, about $159.0M) and open-market sales in 0 filings. Net open-market shares: 8,835,275 (purchases minus sales); net value about $159.0M.Totals add up every open-market (code P and S) line in those filings, using the prices reported in the filings. Awards, option exercises, tax withholding and gifts are listed below but not counted.

Trade dateInsiderTransactionSharesPriceValueOwned afterFiling
2026-08-07Andreessen Marc L
10% owner		 Open-market purchase 1,100,000$18.00 $19.8M10,232,420 SEC
2026-08-07Andreessen Marc L
10% owner		 Conversion 9,132,420— —9,132,420 SEC
2026-08-07Chimovits Erez
Director, 10% owner		 Conversion 9,132,420— —10,235,159 SEC
2026-08-07Chimovits Erez
Director, 10% owner		 Open-market purchase 1,666,667$18.00 $30.0M11,901,826 SEC
2026-08-07Chimovits Erez
Director, 10% owner		 Open-market purchase 273,333$18.00 $4.9M273,333 SEC
2026-08-07Orbimed Genesis Gp Llc
Director, 10% owner		 Open-market purchase 1,666,667$18.00 $30.0M11,901,826 SEC
2026-08-07Orbimed Genesis Gp Llc
Director, 10% owner		 Conversion 9,132,420— —10,235,159 SEC
2026-08-07Orbimed Genesis Gp Llc
Director, 10% owner		 Open-market purchase 273,333$18.00 $4.9M273,333 SEC
2026-08-07Jiangsu Hengrui Pharmaceuticals Co., Ltd.
10% owner		 Conversion 7,420,091— —7,420,091 SEC
2026-08-07Forbion Growth Opportunities Fund Iii Cooperatief U.a.
10% owner		 Conversion 9,132,420— —9,720,546 SEC
2026-08-07Forbion Growth Opportunities Fund Iii Cooperatief U.a.
10% owner		 Open-market purchase 1,680,000$18.00 $30.2M10,185,478 SEC
2026-08-07Forbion Growth Opportunities Fund Iii Cooperatief U.a.
10% owner		 Open-market purchase 1,920,000$18.00 $34.6M11,640,546 SEC
2026-08-07Forbion Growth Opportunities Fund Iii Cooperatief U.a.
10% owner		 Conversion 7,990,867— —8,505,478 SEC
2026-08-07Rickey James Paul
Chief Financial Officer		 Open-market purchase 27,777$18.00 $500.0K520,927 SEC
2026-08-07Viehbacher Christopher
Director		 Open-market purchase 83,333$18.00 $1.5M609,519 SEC
2026-08-07Malek David I
Director		 Open-market purchase 4,166$18.00 $75.0K533,845 SEC
2026-08-07Anderson Michele A.
Chief Development Officer		 Open-market purchase 1,111$18.00 $20.0K332,161 SEC
2026-08-07Murdoch Travis
Director, CEO and President		 Open-market purchase 83,333$18.00 $1.5M2,940,670 SEC
2026-08-07Lubner David Charles
Director		 Open-market purchase 55,555$18.00 $1,000.0K55,555 SEC

Well-known investors holding BRVE (13F)

None of the 59 investors we track reported a position in their latest 13F.

Coming soon: email alerts when BRVE files, watchlists and downloadable comparisons.